Revisiting the benefits of isovolemic hemodilution red cell exchange for sickle cell disease
Journal of Clinical Apheresis · 2023
DOI: 10.1002/jca.22054 ↗At a glance
Journal article in Journal of Clinical Apheresis, 2023. Written by Manasa S Reddy and 3 co-authors. Institution: Transfusion Medicine and Cellular Therapy, Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Major MEDLINE topics: Anemia, Sickle Cell, Hemodilution. Cited 2 times so far (Crossref); 10 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Isovolemic hemodilution red cell exchange (IHD‐RCE) is a modified form of the standard red cell exchange (STD‐RCE), intended to reduce red cell requirements in patients with sickle cell disease (SCD). This retrospective crossover analysis of nine patients aims to add to the limited existing literature on IHD‐RCE and address the equipoise regarding whether the benefits of (a) decreased RBC usage per exchange and (b) increased interprocedure interval (via lower fraction of cells remaining, FCR) can be observed at the same time, in the same patient.
Methods
At a single center, we identified 37 patients with SCD undergoing chronic RCE between 2014 and 2021. We excluded those patients who did not have at least six consecutive procedures of each type (STD‐ and IHD‐RCE), arriving at nine patients for analysis.
Results
When using greater decreases in hematocrit than previously published, we did not find that IHD‐RCE resulted in any clinically apparent adverse events. We did find greater decreases in diastolic blood pressure and increases in heart rate in some patients, as compared to STD‐RCE. After correcting for total blood volume, seven of the nine patients had significantly reduced red cell requirements with each IHD‐RCE. Because the pattern of achieving a lower FCR than programmed was seen to an equal extent with both IHD‐RCE and STD‐RCE, none of the nine patients showed any statistical difference in actual FCR between procedure types.
Discussion
Our data do not support the observation of both IHD‐RCE benefits, decreased red cell usage per exchange and lower FCR/increased interprocedure interval, simultaneously.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Transfusion Medicine and Cellular Therapy, Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Indiana University Health Physicians, Indianapolis, Indiana, USA.
ORCID profiles: Manasa S Reddy, Ahmad Alkashash
Cite
APA
Reddy, M. S., Alkashash, A., Nord, A., & Tetrick, A. (2023). Revisiting the benefits of isovolemic hemodilution red cell exchange for sickle cell disease. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.22054
Vancouver
Reddy MS, Alkashash A, Nord A, Tetrick A. Revisiting the benefits of isovolemic hemodilution red cell exchange for sickle cell disease. Journal of Clinical Apheresis. 2023. doi:10.1002/jca.22054
BibTeX
@article{Reddy2023,
author = {Reddy, Manasa S and Alkashash, Ahmad and Nord, Andrew and Tetrick, Anne},
title = {Revisiting the benefits of isovolemic hemodilution red cell exchange for sickle cell disease},
journal = {Journal of Clinical Apheresis},
year = {2023},
doi = {10.1002/jca.22054}
}
EUVIMED